Detalhe da pesquisa
1.
mTORC2 Regulates Amino Acid Metabolism in Cancer by Phosphorylation of the Cystine-Glutamate Antiporter xCT.
Mol Cell
; 67(1): 128-138.e7, 2017 Jul 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-28648777
2.
Glioblastoma cellular cross-talk converges on NF-κB to attenuate EGFR inhibitor sensitivity.
Genes Dev
; 31(12): 1212-1227, 2017 06 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-28724615
3.
EGFR Mutation Promotes Glioblastoma through Epigenome and Transcription Factor Network Remodeling.
Mol Cell
; 60(2): 307-18, 2015 Oct 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-26455392
4.
A cell type-selective apoptosis-inducing small molecule for the treatment of brain cancer.
Proc Natl Acad Sci U S A
; 116(13): 6435-6440, 2019 03 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-30846550
5.
Glucose-dependent acetylation of Rictor promotes targeted cancer therapy resistance.
Proc Natl Acad Sci U S A
; 112(30): 9406-11, 2015 Jul 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-26170313
6.
High-volume facilities are not always low risk: comparing risk-standardized mortality rates versus facility volume as quality measures in surgical neuro-oncology.
J Neurosurg
; 140(1): 10-17, 2024 Jan 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37410629
7.
Clinical Importance of the lncRNA NEAT1 in Cancer Patients Treated with Immune Checkpoint Inhibitors.
Clin Cancer Res
; 29(12): 2226-2238, 2023 06 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-37053197
8.
Oncogene Amplification in Growth Factor Signaling Pathways Renders Cancers Dependent on Membrane Lipid Remodeling.
Cell Metab
; 30(3): 525-538.e8, 2019 09 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-31303424
9.
An LXR-Cholesterol Axis Creates a Metabolic Co-Dependency for Brain Cancers.
Cancer Cell
; 30(5): 683-693, 2016 Nov 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-27746144
10.
A urokinase receptor-Bim signaling axis emerges during EGFR inhibitor resistance in mutant EGFR glioblastoma.
Cancer Res
; 75(2): 394-404, 2015 Jan 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-25432173
11.
De-repression of PDGFRß transcription promotes acquired resistance to EGFR tyrosine kinase inhibitors in glioblastoma patients.
Cancer Discov
; 3(5): 534-47, 2013 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-23533263
12.
mTOR complex 2 controls glycolytic metabolism in glioblastoma through FoxO acetylation and upregulation of c-Myc.
Cell Metab
; 18(5): 726-39, 2013 Nov 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-24140020
13.
EGFR mutation-induced alternative splicing of Max contributes to growth of glycolytic tumors in brain cancer.
Cell Metab
; 17(6): 1000-1008, 2013 Jun 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-23707073
14.
The mTOR kinase inhibitors, CC214-1 and CC214-2, preferentially block the growth of EGFRvIII-activated glioblastomas.
Clin Cancer Res
; 19(20): 5722-32, 2013 Oct 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-24030701
15.
Old player, new partner: EGFRvIII and cytokine receptor signaling in glioblastoma.
Nat Neurosci
; 19(6): 765-7, 2016 05 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-27227363
16.
Shared Intelligence: A Patient-Derived, Deeply Characterized Glioblastoma Cell Line Resource.
EBioMedicine
; 2(10): 1274-5, 2015 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-26629504